These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells. Salisbury-Ruf CT; Larochelle A J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33535527 [TBL] [Abstract][Full Text] [Related]
3. Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles. Yu KR; Natanson H; Dunbar CE Hum Gene Ther; 2016 Oct; 27(10):729-740. PubMed ID: 27483988 [TBL] [Abstract][Full Text] [Related]
4. Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells. Lee BC; Lozano RJ; Dunbar CE Mol Ther; 2021 Nov; 29(11):3205-3218. PubMed ID: 34509667 [TBL] [Abstract][Full Text] [Related]
5. Gene Editing in Hematopoietic Stem Cells. Liao J; Wu Y Adv Exp Med Biol; 2023; 1442():177-199. PubMed ID: 38228965 [TBL] [Abstract][Full Text] [Related]
6. Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA. Quintana-Bustamante O; Fañanas-Baquero S; Orman I; Torres R; Duchateau P; Poirot L; Gouble A; Bueren JA; Segovia JC PLoS One; 2019; 14(10):e0223775. PubMed ID: 31618280 [TBL] [Abstract][Full Text] [Related]
7. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates. Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391 [TBL] [Abstract][Full Text] [Related]
8. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System. Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170 [TBL] [Abstract][Full Text] [Related]
9. A Curative DNA Code for Hematopoietic Defects: Novel Cell Therapies for Monogenic Diseases of the Blood and Immune System. Porteus MH; Pavel-Dinu M; Pai SY Hematol Oncol Clin North Am; 2022 Aug; 36(4):647-665. PubMed ID: 35773054 [TBL] [Abstract][Full Text] [Related]
10. Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Dudek AM; Porteus MH Front Immunol; 2021; 12():660302. PubMed ID: 34122418 [TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications. Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597 [TBL] [Abstract][Full Text] [Related]
12. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies. Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363 [TBL] [Abstract][Full Text] [Related]
13. An improved medium formulation for efficient Rai R; Naseem A; Vetharoy W; Steinberg Z; Thrasher AJ; Santilli G; Cavazza A Mol Ther Methods Clin Dev; 2023 Jun; 29():58-69. PubMed ID: 36950452 [TBL] [Abstract][Full Text] [Related]
14. Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases. Tucci F; Scaramuzza S; Aiuti A; Mortellaro A Mol Ther; 2021 Feb; 29(2):489-504. PubMed ID: 33221437 [TBL] [Abstract][Full Text] [Related]